Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: A possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis

Tea Kopadze, Thomas Dehmel, Hans Peter Hartung, Olaf Stüve, Bernd C. Kieseier

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Damage of the blood-brain barrier and invasion of immunocompetent cells into the central nervous system represent key events in the immunopathogenesis of multiple sclerosis. Mitoxantrone hydrochloride reduces progression of disability and clinical exacerbations in patients with multiple sclerosis. Its precise mode of action is unclear. Objective: To investigate the effects of mitoxantrone on the migratory capacity of immunocompetent cells ex vivo and in vitro. Design: Case-control study. Setting: Department of Neurology, Heinrich Heine University, Düsseldorf, Germany. Participants: Peripheral blood mononuclear cells (PBMCs) were obtained from 11 patients with multiple sclerosis before and after intravenous mitoxantrone treatment; PBMCs from 5 healthy control donors were treated with mitoxantrone in vitro. Main Outcome Measures: The migratory capacity was studied in an in vitro Boyden chamber assay; cells and their rates of migration were analyzed by light microscopy and flow cytometry. To determine the specificity of our findings, PBMCs were treated with perfosfamide in vitro. Results: Mitoxantrone decreased the migratory capacity of CD14+ monocytes and (to a lesser degree) of CD4 + and CD8+ T lymphocytes. These observations were confirmed when control PBMCs were treated with an equivalent dose of mitoxantrone in vitro. Similar effects were seen when PBMCs were preincubated with perfosfamide. The inhibitory effects of mitoxantrone on the migratory capacity of PBMCs were mediated by reduced matrix metalloproteinase 9 activity, as demonstrated by zymography, polymerase chain reaction, and inhibitory studies. Conclusion: Mitoxantrone may inhibit the migration of inflammatory cells into and within the central nervous system.

Original languageEnglish (US)
Pages (from-to)1572-1578
Number of pages7
JournalArchives of Neurology
Volume63
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Mitoxantrone
Multiple Sclerosis
Cell Movement
Blood Cells
perfosfamide
Therapeutics
Central Nervous System
In Vitro Techniques
Cells
Efficacy
Matrix Metalloproteinase 9
Neurology
Blood-Brain Barrier
Germany
Case-Control Studies
Monocytes
Microscopy
Flow Cytometry
Blood
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Inhibition by mitoxantrone of in vitro migration of immunocompetent cells : A possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. / Kopadze, Tea; Dehmel, Thomas; Hartung, Hans Peter; Stüve, Olaf; Kieseier, Bernd C.

In: Archives of Neurology, Vol. 63, No. 11, 11.2006, p. 1572-1578.

Research output: Contribution to journalArticle

@article{e3c83c3af500407297b777bfb171230e,
title = "Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: A possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis",
abstract = "Background: Damage of the blood-brain barrier and invasion of immunocompetent cells into the central nervous system represent key events in the immunopathogenesis of multiple sclerosis. Mitoxantrone hydrochloride reduces progression of disability and clinical exacerbations in patients with multiple sclerosis. Its precise mode of action is unclear. Objective: To investigate the effects of mitoxantrone on the migratory capacity of immunocompetent cells ex vivo and in vitro. Design: Case-control study. Setting: Department of Neurology, Heinrich Heine University, D{\"u}sseldorf, Germany. Participants: Peripheral blood mononuclear cells (PBMCs) were obtained from 11 patients with multiple sclerosis before and after intravenous mitoxantrone treatment; PBMCs from 5 healthy control donors were treated with mitoxantrone in vitro. Main Outcome Measures: The migratory capacity was studied in an in vitro Boyden chamber assay; cells and their rates of migration were analyzed by light microscopy and flow cytometry. To determine the specificity of our findings, PBMCs were treated with perfosfamide in vitro. Results: Mitoxantrone decreased the migratory capacity of CD14+ monocytes and (to a lesser degree) of CD4 + and CD8+ T lymphocytes. These observations were confirmed when control PBMCs were treated with an equivalent dose of mitoxantrone in vitro. Similar effects were seen when PBMCs were preincubated with perfosfamide. The inhibitory effects of mitoxantrone on the migratory capacity of PBMCs were mediated by reduced matrix metalloproteinase 9 activity, as demonstrated by zymography, polymerase chain reaction, and inhibitory studies. Conclusion: Mitoxantrone may inhibit the migration of inflammatory cells into and within the central nervous system.",
author = "Tea Kopadze and Thomas Dehmel and Hartung, {Hans Peter} and Olaf St{\"u}ve and Kieseier, {Bernd C.}",
year = "2006",
month = "11",
doi = "10.1001/archneur.63.11.1572",
language = "English (US)",
volume = "63",
pages = "1572--1578",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Inhibition by mitoxantrone of in vitro migration of immunocompetent cells

T2 - A possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis

AU - Kopadze, Tea

AU - Dehmel, Thomas

AU - Hartung, Hans Peter

AU - Stüve, Olaf

AU - Kieseier, Bernd C.

PY - 2006/11

Y1 - 2006/11

N2 - Background: Damage of the blood-brain barrier and invasion of immunocompetent cells into the central nervous system represent key events in the immunopathogenesis of multiple sclerosis. Mitoxantrone hydrochloride reduces progression of disability and clinical exacerbations in patients with multiple sclerosis. Its precise mode of action is unclear. Objective: To investigate the effects of mitoxantrone on the migratory capacity of immunocompetent cells ex vivo and in vitro. Design: Case-control study. Setting: Department of Neurology, Heinrich Heine University, Düsseldorf, Germany. Participants: Peripheral blood mononuclear cells (PBMCs) were obtained from 11 patients with multiple sclerosis before and after intravenous mitoxantrone treatment; PBMCs from 5 healthy control donors were treated with mitoxantrone in vitro. Main Outcome Measures: The migratory capacity was studied in an in vitro Boyden chamber assay; cells and their rates of migration were analyzed by light microscopy and flow cytometry. To determine the specificity of our findings, PBMCs were treated with perfosfamide in vitro. Results: Mitoxantrone decreased the migratory capacity of CD14+ monocytes and (to a lesser degree) of CD4 + and CD8+ T lymphocytes. These observations were confirmed when control PBMCs were treated with an equivalent dose of mitoxantrone in vitro. Similar effects were seen when PBMCs were preincubated with perfosfamide. The inhibitory effects of mitoxantrone on the migratory capacity of PBMCs were mediated by reduced matrix metalloproteinase 9 activity, as demonstrated by zymography, polymerase chain reaction, and inhibitory studies. Conclusion: Mitoxantrone may inhibit the migration of inflammatory cells into and within the central nervous system.

AB - Background: Damage of the blood-brain barrier and invasion of immunocompetent cells into the central nervous system represent key events in the immunopathogenesis of multiple sclerosis. Mitoxantrone hydrochloride reduces progression of disability and clinical exacerbations in patients with multiple sclerosis. Its precise mode of action is unclear. Objective: To investigate the effects of mitoxantrone on the migratory capacity of immunocompetent cells ex vivo and in vitro. Design: Case-control study. Setting: Department of Neurology, Heinrich Heine University, Düsseldorf, Germany. Participants: Peripheral blood mononuclear cells (PBMCs) were obtained from 11 patients with multiple sclerosis before and after intravenous mitoxantrone treatment; PBMCs from 5 healthy control donors were treated with mitoxantrone in vitro. Main Outcome Measures: The migratory capacity was studied in an in vitro Boyden chamber assay; cells and their rates of migration were analyzed by light microscopy and flow cytometry. To determine the specificity of our findings, PBMCs were treated with perfosfamide in vitro. Results: Mitoxantrone decreased the migratory capacity of CD14+ monocytes and (to a lesser degree) of CD4 + and CD8+ T lymphocytes. These observations were confirmed when control PBMCs were treated with an equivalent dose of mitoxantrone in vitro. Similar effects were seen when PBMCs were preincubated with perfosfamide. The inhibitory effects of mitoxantrone on the migratory capacity of PBMCs were mediated by reduced matrix metalloproteinase 9 activity, as demonstrated by zymography, polymerase chain reaction, and inhibitory studies. Conclusion: Mitoxantrone may inhibit the migration of inflammatory cells into and within the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=33751010179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751010179&partnerID=8YFLogxK

U2 - 10.1001/archneur.63.11.1572

DO - 10.1001/archneur.63.11.1572

M3 - Article

C2 - 17101825

AN - SCOPUS:33751010179

VL - 63

SP - 1572

EP - 1578

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -